Overview
- Provides the best comprehensive summary of the most important studies book regarding this fundamental tumor suppressor
- If one wants to understand cancer, one must begin by studying p53
- Full color through-out text
- Includes supplementary material: sn.pub/extras
Part of the book series: Protein Reviews (PRON, volume 2)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (10 chapters)
Keywords
About this book
Editors and Affiliations
About the editor
Dr. Gerard Zambetti began working on p53 as a Damon-Runyon Postdoctoral Fellow in the laboratory of Arnie Levine at Princeton University in 1990. During his fellowship he developed the first mammalian promoter-reporter assay to monitor p53 transcriptional activity. A close colleague in the lab, Jamil Momand, identified Mdm2 as a 90 kD protein that binds wild-type p53. At the same time Donna George at Penn reported that Mdm2 promotes tumor growth. They rationalized that Mdm2 could be oncogenic by binding and inactivating p53. This hypothesis was borne out by Dr. Zambetti's demonstration that Mdm2 blocks the ability of p53 to transactivate a wild-type p53 responsive promoter-reporter. These findings established Mdm2 as a negative regulator of p53 and gave rise to the p53-Mdm2 field. Subsequent studies showed that Mdm2 inactivates p53 in human tumors. There is now a biannual international Mdm2 meeting and nearly 2000 published studies regarding Mdm2.
Dr. Zambetti is presently an Associate Member at St. Jude Children’s Research Hospital in Memphis, Tennessee. He has recently been involved in the identification and characterization of a novel germline p53 mutation that selectively predisposes carriers to pediatric adrenal cancer. His lab has also identified cytokine signaling pathways that repress the apoptotic function of p53. These findings could be exploited for the development of strategies to reduce the toxic side effects of radiation and chemotherapy. Dr. Zambetti also studies how p53 becomes activated during cell stress and how it kills tumor cells and his interests continue along these exciting, clinically important lines of research.
Bibliographic Information
Book Title: The p53 Tumor Suppressor Pathway and Cancer
Editors: Gerard P. Zambetti
Series Title: Protein Reviews
DOI: https://doi.org/10.1007/0-387-30127-5
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag US 2005
Hardcover ISBN: 978-0-387-24135-7Published: 11 January 2006
Softcover ISBN: 978-1-4899-9879-8Published: 27 November 2014
eBook ISBN: 978-0-387-30127-3Published: 03 July 2007
Edition Number: 1
Number of Pages: X, 246
Topics: Cancer Research, Oncology, Biochemistry, general, Cell Biology, Medical Biochemistry, Human Genetics